mobile-logo
 

All News

17 Jan

Biosimulation Scientist

by 16by9
in Other News
Comments

Physiomics is an Oxford-based systems biology company specialised in computational modelling of complex biological systems. Our models are based on sets of mathematical equations that simulate key biological processes, and are used by pharmaceutical companies to accelerate their internal drug discovery and development programs. We have an opportunity for a Biosimulation Scientist to join our technical team to work on projects related to drug development....

Read More
11 Nov

Physiomics to present on R&D Developments at the 2011 EORTC-NCI-AACR symposium on “Molecular targets and Cancer Therapeutics”

by 16by9
in Investor News / RNS
Comments

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the EORTC-NCI-AACR symposium on “Molecular Targets and Cancer Therapeutics”, taking place at the Moscone Center West, San Francisco, California on 12-16 November 2011. Dr Eric Fernandez, Project Leader at Physiomics, will present on a prototype version of an anti-cancer drug combination and regimen database. Dr...

Read More
02 Nov

Two new projects in support of Lilly’s Oncology Programs

by 16by9
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), the Oxford, UK based  systems biology company, is pleased to announce that it has signed a further agreement with Eli Lilly and Company ('Lilly'), the global pharmaceutical company, to perform two new projects for in silico simulations in the field of oncology.  The projects involve predicting the outcomes of proposed regimens for two Lilly candidate compounds in combination with other drugs. Read...

Read More
13 Sep

Collaborative Agreement

by 16by9
in Investor News / RNS
Comments

Physiomics Plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a collaborative agreement (“Agreement”) with a wholly owned subsidiary of ValiRx plc (AIM: VAL), ValiPharma Limited, a life science company with a focus on cancer diagnostics and therapeutics for personalized medicine, relating to the further development and accelerated progress of VAL201, ValiPharma’s anti-cancer compound. Read more...

Read More
25 Aug

Publication of book on systems approaches to cancer systems

by 16by9
in Other News
Comments

Physiomics is delighted to announce the publication by Springer of the book ‘Cancer Systems Biology, Bioinformatics and Medicine’ in the Research and Clinical Applications series. Physiomics’ scientists have written the chapter 14 entitled “Systems biology approaches to cancer drug development.” “This teaching monograph on systems approaches to cancer research and clinical applications provides a unique synthesis, by world-class scientists and doctors, of laboratory, computational, and clinical...

Read More
25 May

AACR 2011 posters available for download

by 16by9
in Other News
Comments

The two posters that have been presented at the AACR 102nd Annual Meeting 2011, taking place in the Orange County Convention Center, Orlando, Florida on 2-6 April 2011, are now available for download. The poster  titled "Predicting the effect of combination schedules on xenograft tumor using the Virtual Tumor" presents the validation of our Virtual Tumour platform, which was completed in collaboration with the global...

Read More